Skip to content
Ontario Rheumatology Association
  • Login
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory

Biosimilars, Medical Cannibis, National Pharmacare and More: Executive Director Update

Denis Morrice • Edition: Fall 2018
Denis Morrice

On the Biosimilar Front …

The pan-Canadian Pharmaceutical Alliance (pCPA) has created a guidance document, “Biologics Policy Directions and pCPA Negotiations” and is holding consultation sessions with various stakeholders. Consideration is being given to negotiations for Biosimilars to begin in parallel with the HTA process: tiered listings may be implemented in therapeutic areas where appropriate; switching of patients from reference biologic molecule to a biosimilar may be implemented.

Cancer Care Ontario is supporting the pCPA in launching a cancer-specific strategy to drive the appropriate use and uptake of oncology biosimilars in Canada.

The European Society for Medical Oncology noted the importance of education of all stakeholders, good evidence, and sustainability and impact on healthcare budgets.

The ORA has added a Q&A section to its biosimilar statement on their website at this link: updated position statement. It is important to note that ORA is staying on top of any new evidence, and it is good to see that ORA has been out front on this issue.

On the Cannabis Front …

The Canadian Medical Association (CMA) does not want to be the gatekeeper on Cannabis. Their concern is rooted in the lack of research and pharmaceutical standards re: dosage, potency, risk, and potential complications.

Pharmacists have noted that they are medication experts and are equipped to provide clinical advice to patients and appropriate oversight in the safe management and dispensing of medical cannabis.

Shoppers Drug Mart is now a licensed medical marijuana producer.

The OBRI through CAC and PAC with the support of MedReleaf are designing research questions to help fill the information gap.

The GI Society prepared a video narrated by Dr. James Gray of VGH – worth viewing and sharing with patients. https://www.badgut.org

On the EAP/OHIP+/OPDP Front …

The ORA has presented some 14 items to be addressed during October meetings including policy changes and the TFA situation at OHIP+; EAP approval times and drugs being moved to LU codes; treatment for severe Reynaud’s and Digital Ulcers; Giant Cell Arteritis; Progressive Systemic Sclerosis; form for Vasculitis and more.

A special thank you is owed to Dr. Janet Pope who submitted numerous documents to support treatment for Interstitial Lung Disease along with suggested criteria. The OPDP now wants a full blown submission similar to that required by pharmaceutical companies (that have full time submission and regulatory staff). We believe a medical association and specialists that deal with patients on a day to day basis should be treated quite differently.

On the National Pharmaceutical Front …

The Advisory Council on the Implementation of National Pharmacare are 80% through their stakeholder consultations. A preliminary report is due by Dec 31, 2018 and the final report is scheduled for April 2019. With today’s patchwork of 100 public and 100,000 private insurance plans it is hoped that positive changes will take place. The ORA does its best to have input at the consultations being held by Health Canada, CADTH, PMPRB, pCPA and the Advisory Council.

A reality check: Dr. Purvis and her committee submitted a request to the pCPA for a panCanadian approval and renewal criteria of biologics for RA endorsed by CRA, TAS, CAPA, and CLHIA. Preliminary response: some provinces need to give it more thought. So, if provincial drug program managers can’t agree to move on the ORA request how will they ever agree to a National Pharmacare program?? We are going at it a second time.

On the CADTH Front …

Some positive news: CADTH and INNESS have agreed to jointly engage with clinical specialists to strengthen the current pharmaceutical review process and reduce duplication.

Denis Morrice,

Executive Director, ORA

Other Articles in the Fall 2018 Newsletter

  • OMA Section on Rheumatology Report
  • Locums, Community Elective Program & Third Party Payers Update
  • Informatics Update
  • Communications Update
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association

© 2020 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Annual Awards
  • Events
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • Informatics
  • Members
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • BecomeA Member
  • Renew Membership
  • News
  • Newsletters
  • Drug Shortages Info
  • Other Publications
  • Info Hub
  • Contact
  • Privacy